Related Experiment Video
Updated: Jun 27, 2026
Electromagnetic Source Imaging in Presurgical Evaluation of Children with Drug-Resistant Epilepsy
Published on: September 20, 2024
Anticonvulsant drugs for pediatric migraine prevention: an evidence-based review
Eleni Bakola1, Petros Skapinakis, Meropi Tzoufi
1Postgraduate Program in the Management of Pain, University of Ioannina, School of Medicine, Ioannina, Greece.
Insights
Anticonvulsant drugs for migraine prevention in children and adolescents lack strong evidence. While generally safe, further randomized controlled trials are needed to confirm efficacy for specific agents like topiramate and valproate.
Area of Science:
- Neurology
- Pediatrics
- Pharmacology
Background:
- Anticonvulsant drugs have been previously considered for migraine prevention in pediatric populations.
- Limited high-quality evidence exists to support their routine use.
Purpose of the Study:
- To systematically evaluate the efficacy and safety of anticonvulsant drugs for preventing migraine attacks in children and adolescents.
- To identify gaps in the current research landscape.
Main Methods:
- A comprehensive literature search was conducted to identify relevant studies.
- All study designs, including controlled and uncontrolled trials, were included due to limited data.
- Monthly migraine frequency served as the primary outcome measure.
Main Results:
- Fourteen studies involving 939 patients were analyzed.
- Topiramate, sodium valproate/divalproex sodium, levetiracetam, and zonisamide were the anticonvulsants studied.
- Valproate showed no significant difference from placebo; topiramate's efficacy is uncertain, requiring more randomized trials. All agents were well-tolerated with no serious adverse events.
Conclusions:
- Current evidence from methodologically sound randomized controlled trials is insufficient to support anticonvulsant use for migraine prevention in pediatric patients.
- Further high-quality research is necessary to establish the efficacy and safety of specific anticonvulsant agents in this demographic.
Background:
The use of anticonvulsant drugs for the prevention of migraine in children and adolescents has been supported in the past.
Aims:
To evaluate the available evidence for the efficacy and safety of anticonvulsants drugs in the prevention of migraine attacks in children and adolescents.
Methods:
Studies were selected through a comprehensive literature search. We included all types of study designs (controlled and uncontrolled) due to the limited evidence. Monthly migraine frequency was used as the primary outcome measure in most of the studies. Studies were classified into levels of evidence according to their design.
Results:
Fourteen studies were included with a total of 939 patients. Topiramate (4 randomized controlled trials [RCT], two uncontrolled trials), sodium valproate/divalproex sodium (two RCTs, one uncontrolled trial, two retrospective chart reviews) levetiracetam and zonisamide (both only uncontrolled studies) are the anticonvulsants that have been reported in the literature. The findings show that valproate is not different from placebo and topiramate may not be different but further randomized trials are needed. All drugs were well tolerated in this age group with no serious events reported.
Conclusions:
The use of anticonvulsants in the prevention of migraine in children and adolescents is not adequately supported by methodologically sound RCTs. More research is needed in the future to establish the efficacy and safety of specific agents.
Related Concept Videos
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
01:14Antiepileptic Drugs: Glutamate Antagonists
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:17Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism